ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer
november is Pancreatic
Cancer Awareness Month
Oak Brook, Ill., Nov. 24 /PRNewswire-USNewswire/ -- The American Society for Gastrointestinal Endoscopy (ASGE) and the Pancreatic
Cancer Action Network are teaming up this November to raise awareness about pancreatic
cancer, educating patient...
New Cancer Treatment Shrinks Pancreatic Tumor
NASHVILLE, Tenn., Nov. 24 /PRNewswire/ -- A new cancer treatment is
realizing outstanding results against pancreatic
cancer. Following five weeks
of treatment, a patient's large, stage 4 tumor was reduced in size by 70%.
After seven more weeks of treatment, it no longer could be definitely
RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
- 82% of patients with pancreatic
neuroendocrine tumors (NET) experienced
clinical benefit when treated with daily RAD001 and monthly Sandostatin LAR Depot
- 77% of patients with pancreatic
NET experienced clinical benefit when treated with ...
Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
EAST SETAUKET, N.Y., Aug. 8 /PRNewswire-FirstCall/ -- Lixte
Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) announced today
that lead compounds from each of two different types of drugs being
developed as potential treatment for specific types of brain cancers have
activity against hum...
Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma
CHICAGO and REGENSBURG, Germany, June 2 /PRNewswire/ -- The TGF-beta 2
inhibitor AP 12009, developed by Antisense Pharma, reveals very good safety
and tolerability in the systemic treatment of pancreatic
malignant melanoma and colorectal carcinoma. AP 12009, administered
Patients with Pancreatic Cancer Can Benefit From Avastin(R) Plus Tarceva(R)
- Results Confirm Previously Demonstrated Survival Advantages of Tarceva in This Difficult-to-Treat Disease - ABSTRACT No: 4507
BASEL, Switzerland, May 31 /PRNewswire/ -- Adding Avastin (bevacizumab)
to a combination of Tarceva (erlotinib) and chemothe...
Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
Second Phase Opens With Higher Dose Regimens
SAN MARINO, Calif., April 21 /PRNewswire/ -- Epeius Biotechnologies
Corporation announced today that Interim Analysis of an on-going Phase I/II
study of Rexin-G for pancreatic
cancer confirmed Rexin-G's anti-tumor
activity with no majo...
Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
WALTHAM, Mass., April 16 /PRNewswire-FirstCall/ -- Repligen Corporation
(Nasdaq: RGEN ) announced today that the U.S. Food and Drug Administration
(FDA) has granted Fast Track designation to the development program for
RG1068, synthetic human secretin, to improve the assessment of pancreatic
Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
NEW BRUNSWICK, N.J., April 15 /PRNewswire-FirstCall/ -- Senesco
Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT ) announced today
further details of Dr. Raghavendra Mirmira's preclinical pancreatic
cell research that was funded by the Company. Using a small interfering RNA
Senesco's Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
NEW BRUNSWICK, N.J., April 2, 2008 /PRNewswire-FirstCall/ -- Senesco
Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT ) announced today
that Dr. Raghavendra Mirmira, one of the Company's funded researchers, will
be presenting his findings regarding preclinical pancreatic
islet cell ...
Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
WALTHAM, Mass., March 26 /PRNewswire-FirstCall/ -- Repligen Corporation
(Nasdaq: RGEN ) announced today that the Company has initiated a Phase 3
clinical trial to evaluate the use of RG1068, synthetic human secretin, to
improve the assessment of pancreatic
duct structures by magnetic resonanc...
Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
SOUTH SAN FRANCISCO, Calif., March 13 /PRNewswire/ -- Raven
biotechnologies, inc., a privately held company focused on the discovery
and development of monoclonal antibody therapeutics (MAbs) for cancer,
today announced that it has initiated a Phase 2 study of RAV12, its lead
Mayo Clinic Study Finds Further Association Between Diabetes and Pancreatic Cancer
Study's authors recruit patients for a clinical trial, another step in
this ongoing research
ROCHESTER, Minn., Jan. 23 /PRNewswire-USNewswire/ -- A new Mayo Clinic
study found that 40 percent of pancreatic
cancer patients are diagnosed
with diabetes prior to their pancreatic
EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
Multi-Center Study to Focus on Advanced Cancer Patients
ROCKVILLE, Md., Dec. 4 /PRNewswire-FirstCall/ -- EntreMed, Inc.
(Nasdaq: ENMD ), a clinical-stage pharmaceutical company developing
therapeutics for the treatment of cancer and inflammatory diseases, today
announced that it has c...
Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer
BOULDER, Colo., Oct. 3 /PRNewswire-FirstCall/ -- Tapestry
Pharmaceuticals, Inc. (Nasdaq: TPPH ) announced today that it has initiated
a Phase 2 open- label, multi-center study of TPI 287 in patients with
cancer. This is the second Phase 2 trial exploring the
activity of TP...
Protein Found to Shield Pancreatic Cancer Cells from
HOUSTON, March 20, 2007 - An overexpressed protein
protects human pancreatic
cancer cells from being forced to devour
themselves, removing one of the body's natural defenses against
out-of-control cell growth, researchers at The University of Texas
M. D. Anderson Cancer Center report in the March...
Data Available from Erbitux Phase III Study in First-Line Treatment
of Advanced Pancreatic Cancer
NEW YORK, April 10, 2007 /PRNewswire-FirstCall/ -- ImClone
Systems Incorporated and Bristol-Myers Squibb Company today
announced that a Phase III study of ERBITUX(R) (Cetuximab) plus
gemcitabine (a chemotherapy) in patients with locally advanced
unresectable or metastatic pancreatic
cancer did not...
OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study
Published in the Journal of Clinical Oncology Showed Survival
Improvement in Patients with Pancreatic Cancer
MELVILLE, N.Y.--(BUSINESS WIRE)--Apr 25, 2007 - OSI
Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that results
published yesterday in the Journal of Clinical Oncology show that
adding Tarceva(R) (erlotinib) to gemcitabine chemotherapy
significantly improves survival when administered as firs...
New Data Show Pfizer's Axitinib Prolonged Overall Survival in
Advanced Pancreatic Cancer When Combined with Standard of Care
CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Pfizer announced today that
axitinib (AG-013736), an investigational oral, selective inhibitor
of VEGFR 1, 2,3 (vascular endothelial growth factor receptors 1, 2,
3) combined with gemcitabine showed a trend towards prolonged
overall survival (OS) in patients ...
Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of
GVAX Immunotherapy for Pancreatic Cancer
SOUTH SAN FRANCISCO, Calif., June 04, 2007
/PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announced
follow-up data from a Phase 2 clinical trial of GVAX immunotherapy
cancer which was conducted by the Johns Hopkins
Sidney Kimmel Cancer Center. The trial enrolled 60 patients with...
Skin Rash Actually Signifies Better Outcomes for Pancreatic and
Lung Cancer Patients
PHILADELPHIA, July 3, 2007-- – The appearance of a
rash in cancer patients treated with erlotinib (Tarceva) is
strongly associated with longer survival, according to researchers
from the drug’s developer, OSI Pharmaceuticals, Inc. This is
not the first time that rash has been associate...
Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial
Targeting System's Success in Mouse Model Reported in Cancer Cell
HOUSTON, July 9, 2007 - A molecularly engineered
therapy selectively embeds a gene in pancreatic
cancer that shrinks
or eradicates tumors, inhibits metastasis, and prolongs survival
with virtually no toxicity, researchers from The University of
Texas M. D. Anderson Cancer Center report in the Jul...
Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
... partnership between JDRF and GNF aims to deliver a succession of drug candidates to the clinic over the next four years. The initial focus will be on pancreatic
beta cell regeneration and survival, to restore beta cell function in diabetes. The program builds on current JDRF funding at GNF that has resulted in...
Study Suggests Vitamin D Screening and Appropriate Supplementation Indicated for All Cancer Patients
...ean age at presentation was 55.7 years (SD = 10.2) and the most common cancer types were lung (133, 18%), breast (131, 17.8%), colorectal (97, 13.2%), pancreatic
(86, 11.7%), prostate (44, 6%) and ovarian (38, 5.2%).
Before the study, the researchers hypothesized that malnutrition could contribute to vita...
Researchers Say More Aggressive Vitamin D Supplementation Needed in Obese Cancer Patients
...ears (SD = 10.2). The mean BMI was 27.9 kg/m2 (SD = 6.7). The most common cancers were lung (134, 18.1%), breast (131, 17.7%), colorectal (97, 13.1%), pancreatic
(86, 11.6%), prostate (45, 6.1%) and ovarian (39, 5.3%). The mean vitamin D (serum 25(OH)D) was 21.9 ng/ml (SD = 13.5).
The study concluded that ...
Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines
...ACE, heart attack and stroke) was statistically significant.
RECORD showed no evidence of an increase in malignancies. There were fewer events of pancreatic
cancer in patients taking Avandia although the numbers were small.
"RECORD provides important and reassuring information about Avandia for physi...
TNFerade(TM) Phase III Data Presented at ASCO
...Call/ -- Overall survival data in locally advanced pancreatic
cancer patients treated with TNFerade(TM) in GenVec's ongoing Phase III pancreatic
Cancer Clinical Trial with TNFerade(TM) (PACT) wer...h Chemoradiation in Patients with Locally Advanced pancreatic
Cancer: Interim Analysis of Overall Survival," rep...
Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer
...idates are being developed for the treatment of rheumatoid arthritis, multiple sclerosis and other autoimmune diseases as well as for the treatment of pancreatic
and metastatic breast cancer.
Plexxikon's proprietary Scaffold-Based Drug Discovery(TM) platform integrates multiple state-of-the-art technologie...
Stand Up To Cancer Awards $73.6 Million for Novel, Groundbreaking Cancer Research
"Cutting off the Fuel Supply: A New Approach to the Treatment of pancreatic
Cancer" / Leaders: Craig B. Thompson, M.D., Director, Abramson Cancer Cen...he further development of proposals, where needed, and in two instances (in pancreatic
cancer and breast cancer) where two teams proposed related approaches to re...
BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
...l data generated to date, coupled with a benign side effect profile. Previous clinical trials have enrolled patients with breast cancer, melanoma, and pancreatic
cancer in addition to head and neck cancer, and clinical activity has been observed in each of these cancer types. The Company recently commenced a Ph...
New Report Shows Record Number of Medicines in Development to Treat Leading Causes of Cancer
...or prostate cancer, which this year is expected to kill 28,000 American men. Additional medicines target brain cancer, kidney cancer, ovarian cancer, pancreatic
cancer, skin cancer, and others.
The medicines represent many cutting-edge approaches, including a drug that delivers a synthetic version of a su...
New Cancer Treatment Stops Aggressive Sarcomas
... the great majority of patients so far." The protocol also is offered for qualifying patients with mesothelioma, colon cancer, renal (kidney) cancer, pancreatic
cancer and melanoma.
This investigative treatment is a combination of lovastatin, typically used as a cholesterol lowering agent, and interferon....
Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
... exploring the use of REOLYSIN(R) in combination with chemotherapy for various cancer indications. These indications are expected to include melanoma, pancreatic
cancer, squamous cell lung, liver and K-RAS mutated colorectal cancers in combination with standard chemotherapeutics. This research program is in add...
New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors
...rse mixture of tumors originating from the interface between the endocrine (hormonal) system and the nervous system, and includes carcinoid tumors and pancreatic
NETs. Treatment options for patients with NETs are limited, with surgery being the only chance for cure. When the tumor is inoperable, the objectives ...
Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
...efficiently promote insulin release by beta cells in response to elevated blood glucose levels. In addition, the GDIR is expressed in cells other than pancreatic
beta cells, such as endocrine cells in the gastrointestinal tract, and in preclinical studies the GDIR stimulates the release of GLP and GIP, two incr...
Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
...t (165), ovarian (143), stomach (98), rectal (87), pancreatic
(53), head and neck (36), and other cancers (54) w...and 8.8 percent in the placebo arm). Patients with pancreatic
cancer also experienced a high overall rate of thr...ortionately higher incidence of events in lung and pancreatic
cancer patients, further studies should focus on p...
GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
...eloping novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic
cancer. Additional clinical trials are in progress in rectal cancer, head and neck cancer, and melanoma. GenVec also uses its proprietary adenovector ...
Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
...-27483 inhibits tumor growth in an animal model of pancreatic
previous animal studies, the company ha...nical studies have shown that approximately 90% of pancreatic
express tissue factor. Accordingly, we are...9 to evaluate PCI-27483's effects in
patients with pancreatic
About Factor VII and PCI-27483
FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
...injury, intracranial lesions, or other sources of preexisting increased intracranial pressure. Tapentadol should be used with caution in patients with pancreatic
or biliary tract disease, and moderate hepatic impairment. Because elderly patients are more likely to have decreased renal and hepatic function, cons...
PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients
...ients had nonsense-mutation CF, pathological lung infection, and
insufficiency. In a cross-over design testing 14 days
of PTC124 at two dose...e lung function. In addition, the majority of cystic
fibrosis patients take pancreatic
enzyme supplements to assist with food
absorption in digestion. There is a ...